FOLFOX

FOLFOX
Name	FOLFOX
Specialty	Oncology
Type	Chemotherapy
Uses	Colorectal cancer
Routes	Intravenous therapy
ATC prefix	L01

FOLFOX. It is a widely used chemotherapy regimen primarily for the treatment of colorectal cancer, including in the adjuvant and metastatic settings. The acronym represents its component drugs: Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin. This combination is a cornerstone of modern medical oncology and is administered via intravenous therapy.

Medical uses

The primary indication for this regimen is the management of colorectal cancer. It is a standard of care in the adjuvant therapy following surgical resection for Stage III colorectal cancer, as established by pivotal trials like MOSAIC. In the metastatic setting, it forms the backbone of first-line treatment, often combined with biologic agents such as bevacizumab or cetuximab targeting the epidermal growth factor receptor. Its use has also been explored in other gastrointestinal cancers, including gastric cancer and pancreatic cancer, through clinical studies conducted by groups like the Groupe Coopérateur Multidisciplinaire en Oncologie.

Adverse effects

The toxicity profile is characteristic of its constituent cytotoxic agents. Oxaliplatin is notably associated with dose-limiting neuropathy, including acute cold-induced paresthesia and chronic cumulative sensory neuropathy. Myelosuppression, particularly neutropenia, and gastrointestinal disturbances like mucositis and diarrhea are common due to fluorouracil. Other significant adverse effects can include ototoxicity, nausea and vomiting, and a rare but serious risk of thrombotic microangiopathy. Management often requires dose modifications and supportive care protocols.

Mechanism of action

The regimen exerts its antineoplastic effect through synergistic biochemical inhibition of DNA synthesis and repair. Fluorouracil, a pyrimidine analogue, is metabolically activated to inhibit thymidylate synthase, a key enzyme in de novo thymidine synthesis, thereby causing DNA damage. Folinic acid potentiates this inhibition by stabilizing the binding of fluorouracil metabolites to the enzyme. Oxaliplatin, a platinum compound, forms cytotoxic DNA adducts that distort the DNA helix and trigger apoptosis, with a particular mechanism distinct from older agents like cisplatin.

Dosing regimens

Several standardized schedules exist, defined by specific protocols from cooperative groups like the Groupe Coopérateur Multidisciplinaire en Oncologie. Common variants include FOLFOX4, FOLFOX6, and FOLFOX7, which differ in the timing and dosage of the component drugs. Typically, oxaliplatin and folinic acid are given as a two-hour intravenous infusion, followed by a bolus of fluorouracil and then a continuous infusion over 46 hours. Cycles are repeated every two weeks, with adjustments based on creatinine clearance and the presence of toxicities like neuropathy.

History and development

The regimen evolved from the established use of fluorouracil and leucovorin for colorectal cancer in the late 20th century. The integration of oxaliplatin, developed by the pharmaceutical company Sanofi, marked a significant advance. Its efficacy was conclusively demonstrated in the early 2000s by landmark studies such as the MOSAIC trial, led by investigators including Aimery de Gramont, and the N9741 trial conducted by the North Central Cancer Treatment Group. These studies led to its approval by regulatory bodies like the Food and Drug Administration.

Clinical evidence

Robust data from multiple phase III clinical trials support its use. The MOSAIC trial established its superiority in the adjuvant setting, significantly improving disease-free survival compared to FOLFIRI. In metastatic disease, regimens like FOLFOXIRI (adding irinotecan) have shown efficacy in studies such as those by the GONO group. Comparative effectiveness research, including work by the Mayo Clinic and analyses published in journals like the Journal of Clinical Oncology, continues to refine its role alongside targeted therapies and in personalized medicine strategies based on KRAS mutation status.

Category:Chemotherapy regimens Category:Colorectal cancer